Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Post by rjc7on Feb 09, 2021 7:18am
162 Views
Post# 32510327

GREAT NEWS OUT

GREAT NEWS OUT
MICROBIX ANNOUNCES MATERIAL FIRST SALES OF VIRAL TRANSPORT MEDIUM
GlobeNewswireFEB 09, 2021 07:00 AM EST

Initial Production of 50,000 Vials Entirely Sold

MISSISSAUGA, Ontario, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce material first sales of its viral transport medium (generically known as VTM and branded as DxTM™) that supports Canadian RT-PCR (molecular) testing for the virus causing COVID-19 disease. First sales of 50,000 vials (approximately one lot) have now been made to a private-market client at Microbix’s targeted pricing for this newly-available product. 

At the request of the Government of Ontario, Microbix has created a secure and locally-based supply of high-quality VTM, any shortage of which limits capacity for COVID-19 testing. Microbix has begun its DxTM production at about 50,000 vials per week, with steps now underway to increase that rate of production to 100,000 vials per week and the objective of reaching that doubling in fiscal Q2 (the quarter ended March 31, 2021). Further scale-up and automation is planned to attain Ontario’s original request for production of over 400,000 vials of DxTM per week by the end of Microbix’s fiscal 2021 (September 30, 2021).

Additional production lots will be released on a weekly basis starting this week. Subject to fulfilling orders from the Government of Ontario and its designates, DxTM is now available for use throughout Canada, manufactured and distributed under Microbix’s Health Canada Medical Devices Establishment License (MDEL) and its ISO quality management systems. The suitability of DxTM has been evaluated across multiple test platforms and it is being produced entirely at Microbix’s facilities in Mississauga, Ontario, with its critical ingredients and materials sourced from Canadian suppliers.

Microbix remains engaged with the principal supply-chain organization supporting hospitals in Ontario to procure DxTM for testing programs within the province. However, until Microbix’s supply is procured by the Government of Ontario or its designates, DxTM will continue to be made available on a first-come-first-served basis – including to other provinces and private testing organizations.

DxTM is provided in a vial that is sized to accommodate nasopharyngeal swab segments of up to 10 cm in length. Internal and external studies indicate excellent viral RNA recovery and strong product shelf-life. Further DxTM information is available at www.microbix.com and purchase enquiries can be made by e-mail to customer.service@microbix.com . COVID-19 testing organizations are also encouraged to use Microbix’s PROCEEDx™ “RUO” samples or REDx™ “IVD” controls to support molecular or antigen tests.

Cameron Groome, CEO & President of Microbix, remarked, “We’re honoured to be helping manage the COVID-19 pandemic by making highest-quality viral transport medium here in Ontario. We are likewise pleased our DxTM is now supporting testing efforts within Canada. Microbix’s DxTM can help alleviate the ongoing concerns in Ontario and other provinces about inconsistent quality, intermittent availability, and test-system incompatibilities being experienced with imported supplies.”


<< Previous
Bullboard Posts
Next >>